Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Non-Small Cell Lung Cancer Clinical Trial

Official title: A Phase II Study of Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Who Have Had Prior Treatment With a PD-1 Inhibitor

Status Active, not recruiting

Clinical Trial Summary

This is a Phase II, two part trial (A and B), open label study of Atezolizumab and tiragolumab, or atezolizumab combined with SOC chemotherapy in patients with NSCLC or advanced solid tumors that have had prior treatment with a PD-1 inhibitor (e.g. nivolumab or pembrolizumab).

Clinical Trial Description

Arm A consists of approximately 20 patients with advanced NSCLC who received first-line anti-PD-1 therapy, who have subsequent disease progression. Arm B consists of approximately 15 patients per disease type (renal cell carcinoma [RCC] progressing on prior anti-PD-1 therapy, triple negative breast cancer [TNBC] progressing on prior anti-PD-1 therapy, NSCLC progressing on check-point inhibitors plus chemotherapy in the first-line setting; and microsatellite instability-high [MSI-high] solid tumors [as determined by local testing for MSI/mismatch repair (MMR)] progressing on prior anti-PD-1 therapy). ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Non-Small Cell Lung Cancer
• Solid Tumor

• NCT number: NCT03977467
• Study type: Interventional
• Source: SCRI Development Innovations, LLC
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 30, 2019
• Completion date: July 2024